1 |
Qin, Q., Furong, W., and Baosheng, L. (2014). Multiple functions of hypoxia-regulated miR-210 in cancer. J. Exp. Clin. Cancer Res. 33, 50.
DOI
|
2 |
Rao, Q., Shen, Q., Zhou, H., Peng, Y., Li, J., and Lin, Z. (2012). Aberrant microRNA expression in human cervical carcinomas. Med. Oncol. 29, 1242-1248.
DOI
|
3 |
Tang, X., Chen, L., Yan, X., Li, Y., Xiong, Y., and Zhou, X. (2015). Overexpression of miR-210 is associated with poor prognosis of acute myeloid leukemia. Med. Sci. Monit. 21, 3427-3433.
DOI
|
4 |
Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., and Jemal, A. (2015). Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87-108.
DOI
|
5 |
Wu, S., Huang, S., Ding, J., Zhao, Y., Liang, L., Liu, T., Zhan, R., and He, X. (2010). Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3' untranslated region. Oncogene 29, 2302-2308.
DOI
|
6 |
Yang, W., Sun, T., Cao, J., Liu, F., Tian, Y., and Zhu, W. (2012). Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro. Exp. Cell Res. 318, 944-954.
DOI
|
7 |
Yang, W., Wei, J., Sun, T., and Liu, F. (2013). Effects of knockdown of miR-210 in combination with ionizing radiation on human hepatoma xenograft in nude mice. Radiat. Oncol. 8, 102.
DOI
|
8 |
Yu, S.L., Lee, D.C., Son, J.W., Park, C.G., Lee, H.Y., and Kang, J. (2013). Histone deacetylase 4 mediates SMAD family member 4 deacetylation and induces 5-fluorouracil resistance in breast cancer cells. Oncol. Rep. 30, 1293-1300.
DOI
|
9 |
Zhang, B., Zhang, B., Chen, X., Bae, S., Singh, K., Washington, M.K., and Datta, P.K. (2014). Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway. Br. J. Cancer 110, 946-957.
DOI
|
10 |
Zhang, B., Leng, C., Wu, C., Zhang, Z., Dou, L., Luo, X., Zhang, B., and Chen, X. (2016). Smad4 sensitizes colorectal cancer to 5- fluorouracil through cell cycle arrest by inhibiting the PI3K/Akt/CDC2/survivin cascade. Oncol. Rep. 35, 1807-1815.
DOI
|
11 |
Camps, C., Buffa, F.M., Colella, S., Moore, J., Sotiriou, C., Sheldon, H., Harris, A.L., Gleadle, J.M., and Ragoussis, J. (2008). hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin. Cancer Res. 14, 1340-1348.
DOI
|
12 |
Awang, K., Azmi, M.N., Aun, L.I., Aziz, A.N., Ibrahim, H., and Nagoor, N.H. (2010). The apoptotic effect of 1's-1'-acetoxychavicol acetate from Alpinia conchigera on human cancer cells. Molecules 15, 8048-8059.
DOI
|
13 |
Baez, A., Cantor, A., Fonseca, S., Marcos-Martinez, M., Mathews, L.A., Muro-Cacho, C.A., and Munoz-Antonia, T. (2005). Differences in Smad4 expression in human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck squamous cell carcinoma. Clin. Cancer Res. 11, 3191-3197.
DOI
|
14 |
Baldus, S.E., Schwarz, E., Lohrey, C., Zapatka, M., Landsberg, S., Hahn, S.A., Schmidt, D., Dienes, H.P., Schmiegel, W.H., and Schwarte-Waldhoff, I. (2005). Smad4 deficiency in cervical carcinoma cells. Oncogene 24, 810-819.
DOI
|
15 |
Cheng, H., Fertig, E.J., Ozawa, H., Hatakeyama, H., Howard, J.D., Perez, J., Considine, M., Thakar, M., Ranaweera, R., Krigsfeld, G., et al. (2015). Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma. Cancer Biol. Ther. 16, 1252-1258.
DOI
|
16 |
Gottesman, M.M. (2002). Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615-627.
DOI
|
17 |
Crafton, S.M., and Salani, R. (2016). Beyond chemotherapy: an overview and review of targeted therapy in cervical cancer. Clin. Ther. 38, 449-458.
DOI
|
18 |
Cragg, G.M., and Newman, D.J. (2005). Plants as a source of anticancer agents. J. Ethnopharmacol. 100, 72-79.
DOI
|
19 |
Dang, K., and Myers, K.A. (2015). The role of hypoxia-induced miR- 210 in cancer progression. Int. J. Mol. Sci. 16, 6353-6372.
DOI
|
20 |
Greither, T., Grochola, L.F., Udelnow, A., Lautenschlager, C., Wurl, P., and Taubert, H. (2010). Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int. J. Cancer 126, 73-80.
DOI
|
21 |
Hernanda, P.Y., Chen, K., Das, A.M., Sideras, K., Wang, W., Li, J., Cao, W., Bots, S.J., Kodach, L.L., de Man, R.A., et al. (2015). SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma. Oncogene 34, 5055-5068.
DOI
|
22 |
Ho, C.S., Yap, S.H., Phuah, N.H., In, L.L., and Hasima, N. (2014). MicroRNAs associated with tumour migration, invasion and angiogenic properties in A549 and SK-Lu1 human lung adenocarcinoma cells. Lung Cancer 83, 154-162.
DOI
|
23 |
Jung, E.J., Santarpia, L., Kim, J., Esteva, F.J., Moretti, E., Buzdar, A.U., Di Leo, A., Le, X.F., Bast, R.C., Jr., Park, S.T., et al. (2012). Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 118, 2603-2614.
DOI
|
24 |
Liang, Z., Li, S., Xu, X., Xu, X., Wang, X., Wu, J., Zhu, Y., Hu, Z., Lin, Y., Mao, Y., et al. (2015). MicroRNA-576-3p inhibits proliferation in bladder cancer cells by targeting cyclin D1. Mol. Cells 38, 130-137.
DOI
|
25 |
Kim, Y., Kim, H., Park, D., and Jeoung, D. (2015). miR-335 targets SIAH2 and confers sensitivity to anti-cancer drugs by increasing the expression of HDAC3. Mol. Cells 38, 562-572.
DOI
|
26 |
Klein-Scory, S., Zapatka, M., Eilert-Micus, C., Hoppe, S., Schwarz, E., Schmiegel, W., Hahn, S.A., and Schwarte-Waldhoff, I. (2007). Highlevel inducible Smad4-reexpression in the cervical cancer cell line C4-II is associated with a gene expression profile that predicts a preferential role of Smad4 in extracellular matrix composition. BMC Cancer 7, 209.
DOI
|
27 |
Kloth, J.N., Kenter, G.G., Spijker, H.S., Uljee, S., Corver, W.E., Jordanova, E.S., Fleuren, G.J., and Gorter, A. (2008). Expression of Smad2 and Smad4 in cervical cancer: absent nuclear Smad4 expression correlates with poor survival. Mod. Pathol. 21, 866-875.
DOI
|
28 |
Lagos-Quintana, M., Rauhut, R., Lendeckel, W., and Tuschl, T. (2001). Identification of novel genes coding for small expressed RNAs. Science 294, 853-858.
DOI
|
29 |
Lee, S., Cho, Y.S., Shim, C., Kim, J., Choi, J., Oh, S., Kim, J., Zhang, W., and Lee, J. (2001). Aberrant expression of Smad4 results in resistance against the growth-inhibitory effect of transforming growth factor-beta in the SiHa human cervical carcinoma cell line. Int. J. Cancer 94, 500-507.
DOI
|
30 |
Liu, N., Yu, C., Shi, Y., Jiang, J., and Liu, Y. (2015). SMAD4 expression in breast ductal carcinoma correlates with prognosis. Oncol. Lett. 10, 1709-1715.
DOI
|
31 |
Livak, K.J., and Schmittgen, T.D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method Methods 25, 402-408.
DOI
|
32 |
Lou, M., Jia, Y., Duan, Z., Wu, J., Luo, M., and Wang, Y. (2016). Correlation between human papillomavirus and microRNA-210 in hypoxia-associated human cervical cancer. Int. J. Clin. Exp. Pathol. 9, 1148-1157.
|
33 |
Monk, B.J., Sill, M.W., McMeekin, D.S., Cohn, D.E., Ramondetta, L.M., Boardman, C.H., Benda, J., and Cella, D. (2009). Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 27, 4649-4655.
DOI
|
34 |
Martinez, I., Gardiner, A.S., Board, K.F., Monzon, F.A., Edwards, R.P., and Khan, S.A. (2008). Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene 27, 2575-2582.
DOI
|
35 |
Millimouno, F.M., Dong, J., Yang, L., Li, J., and Li, X. (2014). Targeting apoptosis pathways in cancer and perspectives with natural compounds from mother nature. Cancer Prev. Res. 7, 1081-1107.
DOI
|
36 |
Miyaki, M., Iijima, T., Konishi, M., Sakai, K., Ishii, A., Yasuno, M., Hishima, T., Koike, M., Shitara, N., Iwama, T., et al. (1999). Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene 18, 3098-3103.
DOI
|
37 |
Phuah, N.H., In, L.L., Azmi, M.N., Ibrahim, H., Awang, K., and Nagoor, N.H. (2013). Alterations of microRNA expression patterns in human cervical carcinoma cells (Ca Ski) toward 1'S-1'- acetoxychavicol acetate and cisplatin. Reprod. Sci. 20, 567-578.
DOI
|
38 |
Othman, N., In, L.L., Harikrishna, J.A., and Hasima, N. (2013). Bcl-xL silencing induces alterations in hsa-miR-608 expression and subsequent cell death in A549 and SK-LU1 human lung adenocarcinoma cells. PLoS One 8, e81735.
DOI
|
39 |
Papageorgis, P., Cheng, K., Ozturk, S., Gong, Y., Lambert, A.W., Abdolmaleky, H.M., Zhou, J.R., and Thiagalingam, S. (2011). Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res. 71, 998-1008.
DOI
|
40 |
Phuah, N.H., and Nagoor, N.H. (2014). Regulation of microRNAs by natural agents: new strategies in cancer therapies. Biomed. Res. Int. 2014, 804510.
|